Embolic protection, new stents, and TCAR are narrowing the gap between CAS and CEA, but medical therapy could still hold its own in CREST-2.
HOLLYWOOD, FL—Carotid artery stenting (CAS) and endarterectomy (CEA) remain neck and neck in vying for prominence, but some experts say a minimally invasive surgical approach known as transcarotid artery revascularization (TCAR), as well as new filters and devices that aim to cut the risk of minor stroke with stenting, could well shift the balance away from surgery.
Moreover, still-pending results from the CREST-2 trial will clarify the position of medical therapy compared with revascularization.
“We were running a little bit behind milestones, and I think right now we’re about right at milestones in terms of achieving the actual enrollment,” Barry T. Katzen, MD (Miami Cardiac & Vascular Institute, FL), reported at the 2019 International Symposium on Endovascular Therapy (ISET). “So this trial is moving along quite well, just slightly below the projected accrual rate. Interestingly enough, endarterectomy was lagging behind stenting in terms of accrual, but now it’s pretty much 50-50, which is great news for the ultimate statistical analysis of this trial.”
Read More: https://www.tctmd.com/news/surmounting-minor-stroke-new-devices-tcar-aim-cut-risk-carotid-artery-stenting
1NEWSISET 2019Surmounting Minor Stroke: New Devices, TCAR Aim to Cut Risk of Carotid Artery Stenting
Dr. Michael Aragon and Stacey Porter Bring Wealth of Clinical and Organizational Expertise During Time of Company Grow
A Silicon Valley startup that pioneered a new way to fight diabetes is tackling depression after its CEO noticed a disturbing trend
Via: Business Insider
When Sean Duffy, the cofounder and CEO of a digital-health startup called Omada Health, took his first look at the results of his new diabetes-treatment program, he noticed a disturbing trend.
Blue Cross Blue Shield of Massachusetts Adds Two New Digital Health Solutions for Large Self-insured Clients
Via: PR Newswire
BOSTON, Jan. 8, 2019 /PRNewswire/ -- Blue Cross Blue Shield of Massachusetts (Blue Cross) recently added two new digital health solutions to its Emerging Solutions portfolio—Robin Care for cancer support and Hinge Health for musculoskeletal conditions such as back and knee pain.
Transcarotid artery revascularization with a neuroprotection system was associated with a low rate of stroke in patients with carotid artery stenosis, according to 1-year results of the ROADSTER trial.
Phase 1a Dose-Escalation Data Demonstrates a Favorable Safety Profile and Signals of Immune Cell Modulation in Patients with Late Stage Solid Tumors
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer
Overall Clinical Benefit Rate of 85%, Partial Response Rate of 42% and Progression Free Survival of 5.4 Months Observed in Patients with > 2 Prior Therapies and/or Prior Bevacizumab
Via: Business Wire
GRAND RAPIDS, Mich.--(BUSINESS WIRE)--Today Priority Health announced it will offer a new digital prevention tool to help members manage their diabetes. Through its partnership with Omada Health, Priority Health will provide clinically-eligible members access to Omada, the country’s leading digital Diabetes Prevention Program (DPP), beginning this month. Priority Health is the first health plan in Michigan to add the Centers for Disease Control and Prevention (CDC) fully recognized digital Diabetes Prevention Program as a preventive benefit.
Objective Responses Observed in Heavily-pretreated Ovarian Cancer Patients Treated with Navicixzumab Monotherapy
Cigna Announces Cigna Ventures with $250 Million to Fund Transformative Innovation and Growth for Health Care
BLOOMFIELD, Conn.--(BUSINESS WIRE)--Today, global health service company Cigna (NYSE: CI) announced the launch of Cigna Ventures, a corporate venture fund focused on transformative and innovative health care companies.